Prospective Observational study of Sitagliptin in Subjects with type 2 Diabetes and Chronic Renal Failure
Not Applicable
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-UMIN000016645
- Lead Sponsor
- POSEIDON Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Hypersensitivity to sitagliptin 2) Patients who had severe ketosis or diabetic coma within 6 months 3) Severe infection or trauma, perioperative 4) Receiving glinide therapy 5) Patients whose participation is deemed inappropriate at the discretion of the attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the HbA1c or glycated albumin level at 3 and 6 months after sitagliptin treatment initiation. Adverse events including hypoglycemia and those rates of occurrence
- Secondary Outcome Measures
Name Time Method